VLTS-589 Uses, Dosage, Side Effects and more
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
| Attribute | Details |
|---|---|
| Trade Name | VLTS-589 |
| Generic | VLTS-589 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in peripheral vascular disease.
How VLTS-589 works
VLTS-589 is an investigational nonviral therapeutic comprising a plasmid-expressing Del-1 formulated with poloxamer 188 (facilitating agent). Del-1 plasmid-polaxamer enhances gene transfer at doses that are an order of magnitude different than other comparable trials in a unique bilateral intramuscular dosing pattern to maximize transfection/clinical efficacy and general applicability to patients with peripheral arterial disease (PAD).
